ZYBERNO
Stock Report
Updated Aug 21, 2026

BIODESIX, INC. (BDSX)

Healthcare • NASDAQ

$26.63

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
22.0/100
POOR BUSINESS
BIODESIX, INC. (BDSX) scores 22/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-788.2%)
Debt-to-Equity (Solvency Risk):CRITICAL (5.46x)
Operating Margin (Operational Efficiency):CRITICAL (-20.0%)
Return on Capital (Capital Efficiency):CRITICAL (-19.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BIODESIX, INC. (BDSX) stock report — Zyberno Score 22/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, BDSX generated -$25.10M in Owner Earnings. Capital was deployed as follows: $266.00K invested in capital expenditures. Reinvestment rate: 35.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:26.63
Market Cap:$274.18M

Valuation Multiples (3)

P/B Ratio:29.98x
P/S Ratio:2.66x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$344.19M

Price Action & Momentum (3)

Momentum Percentile:98 / 100
% of 52-Week High:104.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-30.3%
Reinvestment Rate:35.0%
Fundamental Growth Rate (g):-6.8%

Margin Analysis (3)

Operating Margin Ttm:-20.0%
Net Margin Ttm:-27.0%
Ebitda Margin:-13.1%

TTM Performance (2)

Operating Margin Ttm:-20.0%
Net Margin Ttm:-27.0%

Yield Metrics (2)

Earnings Yield:-$25.35
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-143.7%
Latest Earnings Filed:2026-08-05

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):33.3%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.85x
Quick Ratio:2.85x
Cash Ratio:1.96x

Leverage Analysis (3)

Debt To Equity Ttm:5.46x
Debt-to-Equity Ratio:5.46x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-3.44x
Times Interest Earned:-3.44

Capital Structure (4)

Working Capital:28,274,000.00
Cash And Cash Equivalents:29,996,000.00
Long Term Debt:$50.00M
Net Debt:$70.00M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $102.94M
Linear Growth: 33.3%
📊 Click to view full BDSX Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$20.61M

Bottom Line Performance (3)

-$27.76M
Income Before Tax:$0.00
Ebitda Ttm:-13,479,000.00

Operating Expenses (5)

Operating Expenses:123,546,000.00
R And D Expense:12,282,000.00
Sga Expense:93,229,000.00
Income Tax Expense:$0.00
Interest Expense:8,092,000.00

Expense Ratios (3)

R And D To Revenue Percentage:45.7%
Sga To Revenue Percentage:347.1%
Ebitda Margin:-13.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$95.33M
Current Assets:$43.57M
Ppe Net:23,803,000.00
Goodwill:15,031,000.00
Intangible Assets:$2.98M

Liability Structure (4)

Total Liabilities:86,182,000.00
Current Liabilities:15,291,000.00
Long Term Debt:$50.00M
Short Term Debt:$50.00M

Equity & Capital (3)

Equity:$9.14M
Retained Earnings:-$512.83M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:9,113,000.00
Inventory:0.00
Accounts Payable:10,411,000.00

Special Items (2)

Contract Liabilities:205,000.00
Stock Based Compensation:820,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$24.84M-$25.10M

Investment Activities (2)

Investing Cash Flow:-$144.00K
Capital Expenditures Ttm:266,000.00

Financing Activities (3)

Financing Cash Flow:$16.90M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:17,214,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$5.00K

Non-Cash Items (1)

Depreciation Amortization Ttm:7,128,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-6.03
-$6.03
Earnings Per Share Ttm:-$2.70

Revenue & Cash Per Share (2)

Sales Per Share Ttm:10.00
Operating Cash Flow Per Share:-$2.26

Book Value & Capital (2)

Book Value Per Share:$0.89
Cash Per Share:2.91

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.12x
Working Capital Turnover Ttm:3.64x

Receivables Management (2)

Receivables Turnover Ttm:11.30x
Days Sales Outstanding Ttm:32.31

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:36.92
Cash Conversion Cycle:-1,003.60
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$25.10M

Damodaran Growth Analysis (2)

Reinvestment Rate:35.0%
Fundamental Growth Rate (g):-6.8%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):33.3%

Other Growth Rates (1)

Book Value Growth Rate (Linear):1.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:BDSX
Company Name:BIODESIX, INC.
Sector:Healthcare
Industry:Services-Medical Laboratories
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:10.30M
Shares Outstanding Basic:10.30M
Shares Outstanding Diluted:10.30M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-21 20:06:22 UTC
Data Timestamp:2026-08-19T05:05:44.422959
Scroll to Top